Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Charles River Laboratories

Share:
Related CRL
Earnings Scheduled For August 9, 2017
Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Charles River Laboratories (NYSE: CRL), and raised its price target from $35.00 to $44.00.

Jefferies noted, “3Q results were better than expected, making the narrowed 2012 guidance more conservative. Getting $3 in 2013 EPS requires PCS to continue to outgrow the industry with improving margin. Incremental margin was attractive YoY, but negative sequentially. CRL needs RMS to perform better than in 3Q and share the load with PCS, not hand it off. The AZN deal should help. We raise our PT and 2013 estimates.”

Charles River Laboratories closed on Tuesday at $39.40.

Latest Ratings for CRL

DateFirmActionFromTo
Sep 2017RBC CapitalInitiates Coverage OnSector Perform
Jan 2017Evercore ISI GroupUpgradesHoldBuy
Dec 2016Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!
Loading...
Loading...